Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metformin Pharmacogenomics: Current Status and Future Directions

17 Jul 2014

Abstract excerpt

The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variability in response and few clinical or biomarker predictors of response reduce its optimal use. As clinical care moves...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Treatment and Management
Share to Metabolism, Diabetes, and Cancer
Share to Pancreatic function and diabetes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25060887
DOI: 10.2337/db13-1367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metformin Pharmacogenomics: Current Status and Future DirectionsPMID 25060887Read ↗

An Update on the Pharmacogenomics of Metformin: Progress, Problems and PotentialSemantic proximity Read ↗

The pharmacogenetics of metformin.Semantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenetics of metformin response: a step in the path toward personalized medicine.Semantic proximity Read ↗

Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity Read ↗

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical PracticeSemantic proximity Read ↗

Personalized medicine in diabetes: the role of ‘omics’ and biomarkersSemantic proximity Read ↗

Pharmacogenomics of Oral Antidiabetic Medications: Current Data and Pharmacoepigenomic PerspectiveSemantic proximity Read ↗

Diabetes: Genetic variation underpins metformin response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.